Zentalis Pharmaceuticals, Inc. Stock Price, News & Analysis

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has announced the promotion of Cam Gallagher to President. Gallagher, a co-founder and former Executive Director, brings 30 years of experience in life sciences. He will lead corporate and business development initiatives under CEO Dr. Kimberly Blackwell's leadership. Gallagher expressed confidence in Zentalis' potential, especially regarding lead assets ZN-c3 and ZN-d5, as the company advances its clinical strategy. Zentalis focuses on developing small molecule therapeutics targeting biological pathways in cancer.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) has successfully completed an underwritten offering of 10,330,000 shares at $19.38 per share, raising approximately $200.2 million. The proceeds will support ongoing and planned clinical trials for its innovative oncology candidates, including ZN-c3 and ZN-d5, as well as general corporate purposes. The offering was managed by prominent financial institutions including Morgan Stanley and Jefferies. This financing aims to bolster Zentalis's pipeline in the competitive oncology market.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of 10,330,000 shares of common stock at $19.38 per share, totaling approximately $200.2 million in gross proceeds. The offering is expected to close on May 18, 2022, subject to customary conditions. The net proceeds will fund ongoing and planned clinical trials, including ZN-c3 and ZN-d5, and for general corporate purposes. Zentalis aims to maintain sufficient funds for operations until the first quarter of 2025.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced leadership changes, appointing Kimberly Blackwell, MD, as the new CEO, succeeding Anthony Sun, MD, who will continue as CEO of joint venture Zentera Therapeutics. Blackwell, a board member with extensive oncology experience, will focus on accelerating the clinical development of lead candidates ZN-c3 and ZN-d5. Chairman Dave Johnson expressed confidence in the company’s potential, emphasizing their promising pipeline and cash runway.

Zentalis Pharmaceuticals (Nasdaq: ZNTL) announced promising initial data on ZN-c3, a Wee1 inhibitor, from ongoing trials in advanced ovarian cancer and uterine serous carcinoma. The company received a $25 million equity investment from Pfizer to advance clinical development for ZN-c3 and ZN-d5. A Phase 1/2 study for ZN-d5 in relapsed AL amyloidosis has been initiated. As of March 31, 2022, Zentalis reported cash and marketable securities of $289.4 million, providing a cash runway into Q1 2024 after budget reallocations following the Pfizer investment.

Zentalis Pharmaceuticals has entered into a joint clinical development agreement with Pfizer for ZN-c3, a selective Wee1 inhibitor aimed at treating cancer. This partnership includes a $25 million investment from Pfizer through a share offering, expected to close on April 29, 2022. The funding extends Zentalis’ cash runway into Q1 2024, enabling continued clinical trials. Additionally, Pfizer's Adam Schayowitz will join Zentalis’ Scientific Advisory Board to enhance strategic clinical development. The company retains full ownership of its pipeline.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) recently presented promising clinical data for its lead candidate, ZN-c3, at the AACR Annual Meeting. The combination of ZN-c3 with chemotherapy showed an objective response rate (ORR) of 30.2% in advanced ovarian cancer patients. Additionally, in patients with uterine serous carcinoma (USC), ZN-c3 achieved a 27.3% ORR and a 90.9% disease control rate with notable tolerability. The results suggest ZN-c3's potential as a significant therapeutic option in treating advanced cancers.

Zentalis Pharmaceuticals has announced promising results from its ongoing Phase 1b trial of ZN-c3, a potential best-in-class Wee1 inhibitor, in combination with chemotherapy for platinum-resistant ovarian cancer. The treatment demonstrated an overall response rate (ORR) of 30.2% across all evaluated chemotherapy cohorts, with the highest cohort reaching 62.5%. ZN-c3 showed good tolerability, exhibiting a better safety profile than other Wee1 inhibitors. The company plans to advance to a Phase 3 trial based on these results.

Zentalis Pharmaceuticals has announced a strategic collaboration with Caris Life Sciences to enhance patient recruitment for its clinical trials. This partnership will utilize Caris’ advanced molecular profiling to identify candidates for Zentalis’ oncology studies, particularly focusing on the Wee1 inhibitor ZN-c3. Both companies aim to leverage comprehensive genomic data to improve therapeutic development. Zentalis retains full ownership of its candidates while pursuing innovative cancer treatments.